je.st
news
Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting
2014-10-08 17:13:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Interim results of C-SWIFT, a Phase 2 study evaluating ultra-short treatment durations of grazoprevir/elbasvir (MK-5172/MK-8742) plus sofosbuvir, to be presented Results from the C-WORTHy study, a Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742) across multiple patient populations, including difficult-to-cure, to be presented WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical studies of the companys investigational, oral, once-daily, fixed-dose combination chronic hepatitis C treatment grazoprevir/elbasvir (MK-5172/MK-8742) are scheduled to be presented at the 65th American Association for the Study of Liver Diseases (AASLD) Annual Meeting, also known as The Liver Meeting. The meeting is scheduled to take place at the John B. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
data
present
american
Category:Biotechnology and Pharmaceuticals